Thyroid Nodules

Symptoms

• Most thyroid nodules do not cause any symptoms and are often discovered incidentally during imaging tests for other conditions.
• A lump that can be felt or seen in the neck.
• Difficulty swallowing (dysphagia).
• Shortness of breath (dyspnea), especially when lying down.
• Hoarseness or changes in your voice.
• A feeling of a lump in the throat (globus sensation).
• Unexplained weight loss (if the nodule is overactive).
• Heat intolerance (if the nodule is overactive).
• Tremor (if the nodule is overactive).
• Nervousness or anxiety (if the nodule is overactive).
• Rapid or irregular heartbeat (palpitations) (if the nodule is overactive).
• Rapid growth of a nodule (a red flag symptom).
• A very firm or hard nodule (a red flag symptom).
• A nodule that feels fixed to adjacent structures (a red flag symptom).
• Associated swollen lymph nodes in the neck (a red flag symptom).
• Persistent hoarseness (a red flag symptom).

Causes & Risk Factors

• Iodine deficiency, which can lead to compensatory thyroid growth and nodule formation.
• Benign follicular adenoma, an overgrowth of normal thyroid tissue.
• Thyroid cysts, which are fluid-filled cavities often resulting from degenerating adenomas.
• Hashimoto's thyroiditis (chronic lymphocytic thyroiditis), a chronic inflammation of the thyroid gland.
• Multinodular goiter, where multiple areas of the thyroid overgrow, leading to several nodules.
• Thyroid cancer, which accounts for a small percentage (approximately 5-15%) of nodules. The precise molecular reasons for the development of benign nodules are not fully understood but involve genetic and environmental factors influencing follicular cell growth and proliferation.
• Increasing age.
• Being female (thyroid nodules are approximately 4 times more common in women than men).
• A family history of thyroid nodules or thyroid cancer.
• A history of radiation exposure to the head and neck, especially during childhood or adolescence.
• Iodine deficiency, a major risk factor for goiter and nodule formation globally.
• Obesity or metabolic syndrome, which are associated with an increased prevalence of thyroid nodules.
• Iodine excess, which may also be associated with nodule formation.
• Smoking, as some studies suggest a link, particularly with multinodular goiter.

Diagnosis

• A thorough medical history, including personal or family history of thyroid disease or radiation exposure, and any symptoms of compression or thyroid dysfunction.
• A physical examination, involving palpation of the thyroid for size, firmness, and number of nodules, and assessment for swollen lymph nodes in the neck.
• Blood tests, primarily Thyroid-Stimulating Hormone (TSH), which is the initial and most important test. If TSH is low, a radionuclide thyroid scan may be indicated. If TSH is normal or high, a thyroid ultrasound is the next step.
• Serum Calcitonin measurement, if there is a family history of medullary thyroid cancer (MTC) or MEN2.
• Thyroid Antibodies (TPOAb) to help diagnose underlying Hashimoto's thyroiditis.
• Thyroid Ultrasound (US), the primary imaging method, which assesses nodule size, composition, and suspicious features (e.g., microcalcifications, irregular margins).
• Radionuclide Thyroid Scan (Scintigraphy), used only when TSH is low, to determine if a nodule is 'hot' (hyperfunctioning), 'warm' (isofunctioning), or 'cold' (non-functioning). 'Hot' nodules are very rarely malignant.
• Fine-Needle Aspiration (FNA) biopsy, the most accurate and cost-effective method for evaluating thyroid nodules, typically performed under ultrasound guidance.
• The Bethesda System for Reporting Thyroid Cytopathology, a standardized, six-tiered system used to report FNA results and estimate the risk of malignancy (ROM).
• Molecular markers (e.g., Afirma, ThyroSeq) may be used on indeterminate FNA samples (Bethesda III/IV) to help clarify cancer risk and guide management, though specific recommendations and availability may vary.

Treatment Options

• Watchful waiting or active surveillance for nodules confirmed as benign (Bethesda II) on FNA, involving periodic thyroid ultrasound and clinical evaluation.
• Active surveillance for very low-risk thyroid cancers (e.g., papillary microcarcinoma <1 cm) in select patients, as an alternative to immediate surgery.
• Radioactive Iodine (RAI) therapy, effective for treating hyperfunctioning ('hot') nodules that cause hyperthyroidism.
• Levothyroxine (TSH suppression) therapy, generally not recommended for benign nodules in iodine-sufficient populations due to limited efficacy and potential side effects.
• Thyroid lobectomy, the surgical removal of one lobe of the thyroid, often sufficient for smaller, low-risk cancers or indeterminate nodules.
• Total thyroidectomy, the surgical removal of the entire thyroid gland, required for larger or more aggressive cancers, or extensive multinodular goiter.
• Percutaneous Ethanol Injection (PEI), a minimally invasive therapy primarily for cystic nodules.
• Radiofrequency Ablation (RFA), a minimally invasive therapy that uses heat to shrink solid nodules.
• Laser Ablation or High-Intensity Focused Ultrasound (HIFU), other thermal ablation techniques considered as alternatives to surgery in select patients for benign, symptomatic nodules.

Frequently Asked Questions